Ambry
BRCA2 Variants Classified in Saturation Genome Editing Studies
Research teams relied on CRISPR-Cas9-based editing and sequencing to perform high-throughput function evaluations of loss-of-function variants in exons 15 to 26 of BRCA2.
BRCA1/2 Mutations Aren't Equal: Researchers Push for Reduced Penetrance Pathogenic Variant Category
Premium
Researchers worked with two labs to identify 16 consensus lower-risk pathogenic variants and are pushing for greater recognition of such variants.
Ambry Updates Hereditary Cancer Risk Panels With Eye Toward Gene-Disease Validity, Guidelines
Premium
The panels assess genes with strong disease links and clinical management guidelines, but the firm offers limited-evidence genes as an add-on option.
The firm's Q3 2024 revenues rose 33 percent year over year as both its genomics and data and services revenues increased in the double-digit percent range.
New Products Posted to GenomeWeb: Ambry Genetics, Qiagen, Indical Bioscience, More
New products and services posted to GenomeWeb for the week of Sept. 16, 2024.